T1	Participants 140 184	prospective, randomized, double-blind study.
T2	Participants 349 438	prospective double-blind study of empiric antibiotic therapy in granulocytopenic patients
T3	Participants 440 631	Patients were stratified into two groups: favorable-prognosis, group 1 (carcinoma, lymphoma, multiple myeloma), or unfavorable-prognosis, group 2 (acute leukemia, bone marrow transplantation)
